ATS Governance

HomeAboutATS Governance ▶ ATS Leadership
ATS Leadership

M. Patricia Rivera

M. Patricia Rivera, MD, ATSF, originally elected in 2020, will serve as the President.

Dr. Rivera is the C. Jane Davis & C. Robert Davis Distinguished Professor in Pulmonary Medicine, as well as chief, Division of Pulmonary and Critical Care Medicine at the University of Rochester Medical Center. She also serves as adjunct professor of Medicine at the University of North Carolina at Chapel Hill, and the co-director of the North Carolina Lung Screening Registry. Dr. Rivera originally founded the Multidisciplinary Lung Cancer Screening Program at UNC.

2023 Disclosure of Potential Conflicts of Interest Relevant to ATS Activities: Dr. Rivera conducts research supported by the National Institutes of Health focused on comorbidity and functional status of persons undergoing lung cancer screening. She serves as a consultant for American Board of Internal Medicine for pulmonary boards writing committee. She serves as a consultant for the American Cancer Society.


 Irina Petrache, MD, ATSF

Irina Petrache, MD, ATSF, elected in 2021, will serve as the President-Elect. Dr. Petrache will serve as President in 2024-2025.

Dr. Petrache is professor of Medicine at the University of Colorado. She also serves as chief of  Pulmonary, Critical Care and Sleep Medicine, associate vice president of Faculty Development, and Wollowick Chair in COPD Research & Professor of Medicine at National Jewish Health.

2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Petrache is a scientific co-founder of Allinaire Therapeutics which develops novel therapeutics for pulmonary arterial hypertension (PAH) and other pulmonary diseases, including EMAP II. She has conducted research supported by Allinaire, which evolved from work of Dr. Petrache and colleagues as part of the University of Indiana Center for Biomedical Innovation and is funded by Biomotiv. She served as a consultant for Ceramedix for antibody therapies. She has participated in National Institutes of Health-supported research on sphingolipids and the effect of vaping on lung parenchyma.


Raed A. Dweik

Raed A. Dweik, MD, MBA, ATSF, elected in 2023, will serve as the Secretary. Dr. Dweik will serve as President in 2025-2026.

Dr. Dweik currently holds the E. Tom and Erica Meyer Endowed Professorship and serves as chair of the Respiratory Institute (RI) at Cleveland Clinic Health System (CCHS). He will serve as secretary during the 2023-2024 term and as president for 2025-2026. At the ATS, he is a member of the Pulmonary Circulation Assembly, serving on the Finance (2022-curent) and Planning and Evaluation (2022-2023) Committees. Previously, he served on the Education (2010-2015), Ethics and Conflict of Interest (2015-2016), Quality Improvement and Implementation (2016-2017) Committees, and the Document Development and Implementation Committee (2013-2020, chair: 2016-2020).

2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Dweik is an investigator and inventor on a Joint Development and Option agreement between Cleveland Clinic and BreathTech Corporation, a wholly owned subsidiary of Astrotech Corporation. The aim of the research project is to develop a rapid breath test for coronavirus infection or related indicators. Dr. Dweik is entitled to commercialization revenues as an inventor on the intellectual property.


Jesse Roman, MD

Jesse Roman, MD, originally elected in 2022, will serve as the ATS Treasurer through 2025.

Dr. Roman has been a member of the ATS since 1988, and he is committed to diversity, equity and inclusion, having served as a founding leader of the Health Equity Subcommittee within the Health Equity and Diversity Committee. He is currently with Jefferson Health in Philadelphia, Pa, where he serves as the Ludwig Kind Professor of Medicine; enterprise division chief, Pulmonary, Allergy and Critical Care Medicine; and director of the Pulmonary and Critical Care Medicine Fellowship Program. Dr. Roman also serves as CEO of the Jane & Leonard Korman Respiratory Institute of Jefferson Health and National Jewish Health.

2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Roman has served on a data safety and monitoring board for Novartis for anti-fibrotic treatment. He has received industry-sponsored research support to his institution for anti-fibrotic treatment from F. Hoffmann-LaRoche, Horizon Therapeutics, Galapagos, Syneos Health, Boehringer Ingelheim, Bellerophon Therapeutics, Fibrogen. He has served as a consultant for Boehringer Ingelheim developing national registry designed to obtain real life data about interstitial lung disorders.


Gregory P. Downey

Gregory Downey, MD, ATSF, originally elected in 2019, will serve as the Immediate Past-President.

Dr. Downey is a professor of medicine, pediatrics, and immunology and genomic medicine at National Jewish Health where he also serves as executive vice president of Academic Affairs, and provost. He is also professor of medicine and immunology and microbiology and associate dean of Health Affairs at the University of Colorado in Denver.

2023 Disclosure of Potential Conflicts of Interests Relevant to ATS Activities: Dr. Downey has served on the Board of Directors of the Lovelace Respiratory Institute and as a consultant for Angion in the development of novel anti-fibrotic compounds. No payments have been received from Angion. He previously served as a consultant for Biomotiv in the development of novel anti-inflammatory compounds. He served as a consultant for Altimmune for antiviral therapies. Dr. Downey served as a consultant for Translate Bio for ARDS treatment. He has served on a scientific advisory committee for the LAM Foundation.


Karen J. Collishaw, MPP, CAE

Karen J. Collishaw, MPP, CAE, is Chief Executive Officer of the American Thoracic Society (ATS), a professional organization that comprises over 16,000 physicians, research scientists, nurses and other health professionals with a mission to accelerate global innovation in the advancement of respiratory health through multidisciplinary collaboration, education, and advocacy.

Prior to joining the ATS in May 2018, Ms. Collishaw was the President & CEO of the Community Health Accreditation Program (CHAP), an independent, not-for-profit accrediting body for community-based health care organizations. Previously, Ms. Collishaw served in executive leadership positions with two professional medical societies--the American Academy of Dermatology and the American College of Cardiology (ACC). She was responsible for activities related to science, research, advocacy, quality and managed ACC’s annual scientific session.

Following the completion of a Bachelor of Arts in Government from Cornell University, Ms. Collishaw started her career working for the U.S. House of Representatives and then in Battelle Memorial Institute’s Washington office. She earned a Master of Public Policy degree from Georgetown University, is a Certified Association Executive, and past president of the American Association of Medical Society Executives.